The company said its sample preparation technology uses nanomagnetic particles that can reduce the effects of complex interferences in patient samples.
Following a lengthy discovery period, the lab is asking a South Carolina federal district court to find in its favor and decide that its negligence did not result in the death of Williams' son.
Such an approach could be more specific for Alzheimer's than symptoms-based diagnoses while also allowing for earlier detection and treatment of the condition.
Evogen launched a clinical trial to further validate its proteomic test for distinguishing between epileptic seizures and psychogenic non-epileptic seizures.
